Instituto Ramón y Cajal de Investigación Sanitaria -ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2022

  1. Causes of hyperprolactinaemia in the primary care setting: How to optimise hyperprolactinaemia management

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 10, pp. 771-778

  2. Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis

    Multiple Sclerosis and Related Disorders

2017

  1. Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3

    PLoS ONE, Vol. 12, Núm. 4

  2. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies

    Methods in Enzymology (Academic Press Inc.), pp. 175-198

2016

  1. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

    Neuroscience, Vol. 339, pp. 191-209

2014

  1. Cannabinoids and the brain: New hopes for new therapies

    Cannabinoids (John Wiley and Sons Ltd), pp. 175-218

  2. Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

    British Journal of Pharmacology, Vol. 171, Núm. 6, pp. 1472-1489

2012

  1. Chromenopyrazoles: Non-psychoactive and Selective CB 1 Cannabinoid Agonists with Peripheral Antinociceptive Properties

    ChemMedChem, Vol. 7, Núm. 3, pp. 452-463